STOCK TITAN

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
private placement

MAIA Biotechnology announced that independent director Stan V. Smith, Ph.D. purchased 100,000 shares of common stock and warrants to purchase an additional 100,000 shares for a total of $225,900 in the company's recent private placement. The transaction, announced on October 28, 2024, closed on November 1, 2024. Smith, one of MAIA's original investors, has participated in nearly every private placement financing round since the company's inception. As president of Smith Economics Group, , he expressed confidence in MAIA's THIO franchise's potential in treating multiple difficult-to-treat cancer types through telomere targeting and immunogenicity.

MAIA Biotechnology ha annunciato che il direttore indipendente Stan V. Smith, Ph.D., ha acquistato 100.000 azioni di azioni ordinarie e warrant per acquistare ulteriori 100.000 azioni per un totale di 225.900 dollari nell'ambito dell'ultima operazione di collocamento privato dell'azienda. La transazione, annunciata il 28 ottobre 2024, si è conclusa il 1 novembre 2024. Smith, uno degli investitori originali di MAIA, ha partecipato a quasi tutti i round di finanziamento di collocamento privato sin dalla fondazione dell'azienda. In qualità di presidente del Smith Economics Group, ha espresso fiducia nel potenziale del franchise THIO di MAIA nel trattare diversi tipi di tumore difficili da trattare, attraverso la targeting dei telomeri e l'immunogenicità.

MAIA Biotechnology anunció que el director independiente Stan V. Smith, Ph.D., adquirió 100,000 acciones de acciones ordinarias y warrants para comprar 100,000 acciones adicionales por un total de $225,900 en la reciente colocación privada de la compañía. La transacción, anunciada el 28 de octubre de 2024, se cerró el 1 de noviembre de 2024. Smith, uno de los inversores originales de MAIA, ha participado en casi todas las rondas de financiamiento de colocación privada desde la creación de la empresa. Como presidente del Smith Economics Group, expresó su confianza en el potencial de la franquicia THIO de MAIA para tratar múltiples tipos de cáncer difíciles de tratar a través de la focalización de telómeros y la inmunogenicidad.

MAIA Biotechnology는 독립 이사인 Stan V. Smith 박사가 100,000주의 보통주와 추가로 100,000주를 구매할 수 있는 워런트를 구입하여 총 $225,900에 이르는 최근의 사모 배치에서 구매했다고 발표했습니다. 이 거래는 2024년 10월 28일에 발표되어 2024년 11월 1일에 종료되었습니다. MAIA의 최초 투자자 중 한 명인 Smith는 회사 설립 이후 거의 모든 사모 배치 자금 조달 라운드에 참여했습니다. Smith Economics Group의 회장으로서, 그는 MAIA의 THIO 프랜차이즈가 텔로미어 타겟팅과 면역원성을 통해 치료하기 어려운 여러 암 유형을 치료할 수 있는 잠재력에 대한 자신감을 표현했습니다.

MAIA Biotechnology a annoncé que le directeur indépendant Stan V. Smith, Ph.D., a acheté 100 000 actions ordinaires ainsi que des warrants pour acheter 100 000 actions supplémentaires pour un total de 225 900 $ dans le cadre de la récente émission privée de l'entreprise. La transaction, annoncée le 28 octobre 2024, s'est clôturée le 1er novembre 2024. Smith, l'un des premiers investisseurs de MAIA, a participé à presque toutes les rondes de financement par émission privée depuis la création de l'entreprise. En tant que président du Smith Economics Group, il a exprimé sa confiance dans le potentiel de la franchise THIO de MAIA pour traiter plusieurs types de cancer difficiles à traiter grâce à la ciblage des télomères et à l'immunogénicité.

MAIA Biotechnology gab bekannt, dass der unabhängige Direktor Stan V. Smith, Ph.D., 100.000 Aktien von Stammaktien und Warrants zum Kauf weiterer 100.000 Aktien für insgesamt 225.900 $ im Rahmen der jüngsten Privatplatzierung des Unternehmens erwarb. Die Transaktion, die am 28. Oktober 2024 bekannt gegeben wurde, wurde am 1. November 2024 abgeschlossen. Smith, einer der ursprünglichen Investoren von MAIA, hat seit der Gründung des Unternehmens an nahezu jeder Finanzierungsrunde für Privatplatzierungen teilgenommen. Als Präsident der Smith Economics Group äußerte er Vertrauen in das Potenzial der THIO-Franchise von MAIA zur Behandlung mehrerer schwer behandelbarer Krebsarten durch Telomerzielung und Immunogenität.

Positive
  • Director's significant personal investment of $225,900 demonstrates insider confidence
  • Successful completion of private placement financing round
Negative
  • Reliance on private placement financing indicates potential cash needs
  • Warrant issuance may lead to future dilution for shareholders

Insights

The $225,900 investment by director Stan Smith represents a significant insider purchase, accounting for approximately 0.29% of MAIA's market cap. While the investment amount is modest in absolute terms, the director's continued participation in financing rounds signals confidence in the company's direction. The purchase includes both shares and warrants, effectively doubling the potential investment exposure through future warrant exercise rights. The timing of this investment, following closely after the broader private placement, suggests management's alignment with shareholder interests. However, investors should note that insider purchases, while positive signals, don't guarantee future performance. The company's focus on telomere-targeting therapeutics in oncology remains a speculative investment given its clinical-stage status.

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 100,000 shares of MAIA’s common stock, and warrants to purchase 100,000 shares, of MAIA’s common stock for an aggregate purchase price of $225,900 as part of the Company’s recent private placement of common stock and warrants announced by the Company on October 28, 2024, and which closed on November 1, 2024.

“As one of our original investors, Stan has participated in nearly every private placement financing round since our Company’s inception. We are grateful for his consistent participation in our financings and for his long-time service on our Board,” said Vlad Vitoc, M.D., Chairman and CEO of MAIA.

Stan Smith, Ph.D. commented, “As a private investor in MAIA, I believe the science behind the THIO franchise, coupling telomere targeting and immunogenicity, can be disruptive in the treatment markets for multiple difficult-to-treat cancer types.”

Dr. Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.

Additional details on the private placement can be found in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2024, at www.sec.gov.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact

+1 (872) 270-3518

ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

FAQ

How many shares did Stan Smith purchase in MAIA Biotechnology's private placement?

Stan Smith purchased 100,000 shares of common stock and warrants to purchase an additional 100,000 shares for a total investment of $225,900.

When did MAIA Biotechnology's recent private placement close?

MAIA Biotechnology's private placement closed on November 1, 2024, after being announced on October 28, 2024.

What is the focus of MAIA Biotechnology's THIO franchise?

MAIA's THIO franchise focuses on telomere targeting and immunogenicity for treating multiple difficult-to-treat cancer types.

MAIA Biotechnology, Inc.

NYSE:MAIA

MAIA Rankings

MAIA Latest News

MAIA Stock Data

53.70M
21.15M
17.49%
7.51%
2.76%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHICAGO